Sign in
Taking peoplePhase 2

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France19 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
2,000 people, planned
Started
9 Jul 2026
Expected to end
9 Jul 2031
Type of study
Interventional, 24 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tocilizumab
  • Baricitinib
  • Anakinra
  • Hydrocortisone
  • Hydrocortisone and fludrocortisone
  • Heparin
  • Low molecular weight heparin
  • Recombinant humanThrombomodulin( rhTM)
  • Sivelestat
  • Usual care
  • blood purification with MTx.100 Plasma Adsorption Column
  • G-CSF filgrastim
  • Interferon gamma-1b
  • Fludrocortisone
  • Prophylactic unfractionated heparin (UFH)
  • Octaplas LG
  • Plasminogen
Record updated
20 October 2026

Who can take part

Age
37 weeks and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Other criteria

  • Platform inclusion criteria will be:
  • All genders patients
  • Aged >37 weeks corrected gestational age
  • Sepsis as per Sepsis-3 definition for adults, and as per the PHOENIX sepsis for children; Briefly, all following criteria will be required:
  • Documented or suspected infection,
  • Sequential Organ Failure Assessment (SOFA) score ≥2 for adults, and PHOENIX sepsis score of ≥2 for children; Health insurance; Platform exclusion criteria:; Any of the following:
  • Refusal to consent for participating in the study,
  • Pregnancy measured by beta-HCG blood levels
  • Breast feeding
  • Acute coronary disease in the past 3 months
  • Stroke episode in the past 3 months
  • Any condition for which patient's primary physician will consider inappropriate enrolling patient in the study; Treatable trait inclusion criteria :
  • Hyperinflammation : Subphenotypes Beta, Delta, Gamma for adults; Subphenotypes PedSep-B, C, D for children
  • Hypoinflammation : lymphocytes count < 1.0 × 10\^9/L
  • Macrophage Activation Like Syndrome : Ferritin >4,420 ng/mL for adults, Ferritin >500 ng/mL for children
  • Corticosteroids: Positive for i-RECORDS algorithm signature
  • Hypercoagulation (adults) : Prothrombin time (PT)/INR ≥ 1.40 AND Platelet count < 150 000/mm3 or greater than 30% decrease in platelets in 24 hours
  • Hypofibrinolysis (adults): Plasminogen deficit < 0.5 µmol/L; There are also inclusion and exclusion criteria related to treatable traits and interventions

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

The 24 groups in the trial

  • Hyperinflammation : TocilizumabTreatment being tested

    Treatment: Tocilizumab

  • Hyperinflammation: BaricitinibTreatment being tested

    Treatment: Baricitinib

  • Hyperinflammation: AnakinraTreatment being tested

    Treatment: Anakinra

  • Hyperinflammation : blood purification with MTx.100 Plasma Adsorption ColumnTreatment being tested

    Treatment: blood purification with MTx.100 Plasma Adsorption Column

  • Hyperinflammation : usual careExisting treatment, for comparison

    Treatment: Usual care

  • Hypoinflammation : G CSF filgrastimTreatment being tested

    Treatment: Heparin and G-CSF filgrastim

  • Hypoinflammation : Interferon gamma-1bTreatment being tested

    Treatment: Interferon gamma-1b

  • Hypoinflammation : usual careExisting treatment, for comparison

    Treatment: Usual care

  • MALS : AnakinraTreatment being tested

    Treatment: Anakinra

  • MALS : blood purification with MTx.100 Plasma Adsorption ColumnTreatment being tested

    Treatment: blood purification with MTx.100 Plasma Adsorption Column

  • MALS : usual careExisting treatment, for comparison

    Treatment: Usual care

  • Corticoids response : HydrocortisoneTreatment being tested

    Treatment: Hydrocortisone

  • Corticoids response : FludrocortisoneTreatment being tested

    Treatment: Fludrocortisone

  • Corticoids response : Hydrocortisone + FludrocortisoneTreatment being tested

    Treatment: Hydrocortisone and fludrocortisone

  • Corticoids response : usual careExisting treatment, for comparison

    Treatment: Usual care

  • Hypercoagulation : Prophylactic unfractionated heparin (UFH)Treatment being tested

    Treatment: Prophylactic unfractionated heparin (UFH)

  • Hypercoagulation : Therapeutic UFHTreatment being tested

    Treatment: Heparin

  • Hypercoagulation : Therapeutic low molecular weight heparin (LMWH)Treatment being tested

    Treatment: Low molecular weight heparin

  • Hypercoagulation : ThrombomodulinTreatment being tested

    Treatment: Recombinant humanThrombomodulin( rhTM)

  • Hypercoagulation : usual careExisting treatment, for comparison

    Treatment: Usual care

  • Hypofrinolysis : SivelestatTreatment being tested

    Treatment: Sivelestat

  • Hypofrinolysis : OctaplasLGTreatment being tested

    Treatment: Octaplas LG

  • Hypofrinolysis : PlasminogenTreatment being tested

    Treatment: Plasminogen

  • Hypofrinolysis : Usual careExisting treatment, for comparison

    Treatment: Usual care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
Record updated
20 October 2026